HER-2 Specific CAR T Cell

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameHER-2 Specific CAR T Cell
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionAnti-HER2
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsEpendymoma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research Hospital
China Registration ClassN/A

Develop Information

Active CompaniesPediatric Brain Tumor Consortium (Pbtc), St. Jude Children'S Research HospitalNational Cancer Institute
Inactive CompaniesN/A
Active IndicationsEpendymoma
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A